Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease

COPD Clinical Trial

Official title:

Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03184727
• Other study ID #: 2016YFC1304405
• Status: Recruiting
• Phase: N/A
• First received: June 8, 2017
• Last updated: June 13, 2017
• Start date: June 15, 2017
• Est. completion date: December 31, 2020

Study information

• Verified date: June 2017
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: Jianguo He He, MD
• Phone: 80-10-88398060
• Email: hejianguofw[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The pulmonary vasculopathy and right heart dysfunction in COPD are drawing increasing attention these days. Recent researches show that pulmonary vasculopathy and right heart dysfunction relate to greater severity in COPD. Applying appropriate modalities for early detection of pulmonary vasculopathy and right heart dysfunction is of great importance. What's more, the interaction mechanism between pulmonary vasculature, right heart and COPD still needs to be further studied. The aim of our study is to develop an assessment system of pulmonary vasculopathy and right heart dysfunction in COPD patients and elucidate their impact on COPD course and outcome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• stable COPD patients

Exclusion Criteria:

• patents with other respiratory diseases and pulmonary hypertension other than group 3 PH;

• psychopath, addict or patients not able to coordinate;

• patients in pregnancy or breastfeeding;

• patients with limited life expectancy;

• patients with contraindiction for MRI or PET;

• patients having cerebrovascular events in 3 months;

• unstable COPD patients

Related Conditions & MeSH terms

• COPD
• Pulmonary Vascular Disorder
• Right Ventricular Dysfunction
• Vascular Diseases
• Ventricular Dysfunction
• Ventricular Dysfunction, Right

Locations

Country	Name	City	State
China	Cardiovascular Institute and Fu Wai Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	survival rate in %	3 years
Secondary	COPD exacerbations	total times	3 year
Secondary	GOLD degree	?-? according to the pulmonary function	3 year
Secondary	NYHA degree	?-? according to the symptom	3 year